Soligenix's Losses Widen Amid Soaring R&D Costs, Cash Dwindles

TL;DR

**SNGX is burning cash fast with R&D, and with the ATM facility exhausted, they're going to need more dilution or a miracle to stay afloat past Q1 2026.**

AI Summary

SOLIGENIX, INC. (SNGX) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $5,653,244, compared to a net loss of $3,559,829 for the same period in 2024. This 58.8% increase in net loss was primarily driven by a substantial rise in research and development expenses, which surged to $3,618,694 in 2025 from $1,596,198 in 2024, representing a 126.7% increase. The company generated no grant revenue in the first half of 2025, a sharp decline from $119,371 in 2024. Cash and cash equivalents decreased to $5,097,670 as of June 30, 2025, from $7,819,514 at December 31, 2024. SNGX utilized $4,588,835 in cash for operating activities during the six months ended June 30, 2025. The company is actively enrolling patients for its second Phase 3 FLASH2 study for HyBryte in CTCL, with top-line results anticipated in the second half of 2026. SNGX also sold 978,105 shares of common stock through its At Market Issuance Sales Agreement, generating $3,243,177 in gross proceeds during the six months ended June 30, 2025, and an additional $1,439,300 from July 1, 2025, through August 7, 2025, exhausting its ATM facility.

Why It Matters

Soligenix's escalating net loss and dwindling cash reserves raise significant concerns for investors, highlighting the high-risk nature of biopharmaceutical development. The company's reliance on equity offerings, like the recently exhausted ATM facility, indicates a continuous need for capital, which could lead to further shareholder dilution. For employees, the going concern warning could create uncertainty, while customers awaiting HyBryte's approval face potential delays if funding issues persist. In the competitive biotech landscape, SNGX's financial instability could hinder its ability to advance critical clinical trials and bring products to market, potentially impacting its long-term viability against better-capitalized rivals.

Risk Assessment

Risk Level: high — The company explicitly states that it does not have sufficient cash and cash equivalents to fund operations for at least 12 months following the issuance of these financial statements, raising "substantial doubt about the Company's ability to continue as a going concern." This is further evidenced by an accumulated deficit of $239,623,996 and a net loss of $5,653,244 for the six months ended June 30, 2025.

Analyst Insight

Investors should exercise extreme caution and consider selling SNGX shares due to the explicit going concern warning and significant cash burn. The company's reliance on future financing, without assurance of success, presents a high risk of further dilution or operational curtailment. Monitor for any successful strategic partnerships or significant grant funding announcements, but do not invest based on current financials.

Financial Highlights

debt To Equity

2.15

revenue

$0

operating Margin

N/A

total Assets

$5,760,647

total Debt

$3,931,696

net Income

($5,653,244)

eps

N/A

gross Margin

N/A

cash Position

$5,097,670

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $5,653,244 — Net Loss (Increased from $3,559,829 in 2024 for the six months ended June 30)
• $3,618,694 — Research and Development Expenses (Increased from $1,596,198 in 2024 for the six months ended June 30)
• $5,097,670 — Cash and Cash Equivalents (Decreased from $7,819,514 at December 31, 2024)
• $239,623,996 — Accumulated Deficit (As of June 30, 2025)
• $4,588,835 — Net Cash Used in Operating Activities (For the six months ended June 30, 2025)
• $3,243,177 — Proceeds from ATM Sales Agreement (Gross proceeds from issuance of common stock for the six months ended June 30, 2025)
• 978,105 — Shares Issued via ATM (For the six months ended June 30, 2025)
• $1,439,300 — Additional ATM Proceeds (From July 1, 2025, through August 7, 2025, exhausting the facility)

Key Players & Entities

• SOLIGENIX, INC. (company) — registrant
• A.G.P./Alliance Global Partners (company) — At Market Issuance Sales Agreement partner
• European Medicines Agency (regulator) — agreed on FLASH2 study design
• U.S. Food and Drug Administration (regulator) — awarded Orphan Products Development grant
• National Institute of Allergy and Infectious Diseases (regulator) — government grant and contract funding source
• Biomedical Advanced Research and Development Authority (regulator) — government grant and contract funding source
• Defense Threat Reduction Agency (regulator) — government grant and contract funding source
• Nasdaq Capital Market (regulator) — exchange where common stock is registered

FAQ

Risk Factors

• Increasing Net Loss and Burn Rate [high — financial]: The company reported a net loss of $5,653,244 for the six months ended June 30, 2025, a 58.8% increase from $3,559,829 in the same period of 2024. This is largely due to a 126.7% surge in R&D expenses to $3,618,694. The company also utilized $4,588,835 in cash for operating activities, indicating a high burn rate.
• Declining Cash Position [high — financial]: Cash and cash equivalents decreased to $5,097,670 as of June 30, 2025, down from $7,819,514 at December 31, 2024. This reduction, coupled with the operating cash burn, raises concerns about future liquidity.
• Reliance on Equity Financing [medium — financial]: The company sold 978,105 shares generating $3,243,177 in gross proceeds through its ATM facility in the first half of 2025, and an additional $1,439,300 thereafter, exhausting the facility. This reliance on equity issuance dilutes existing shareholders and highlights a need for sustainable revenue generation.
• Clinical Trial Risks [high — regulatory]: The company is actively enrolling patients for its second Phase 3 FLASH2 study for HyBryte in CTCL, with results anticipated in the second half of 2026. Delays, adverse outcomes, or regulatory hurdles in these trials could significantly impact the company's future prospects.
• Dependence on Key Product Development [high — operational]: The company's primary focus appears to be on the development and potential commercialization of HyBryte. Any setbacks in its development or regulatory approval process pose a significant risk to the company's business model.
• Accumulated Deficit [high — financial]: As of June 30, 2025, the company has an accumulated deficit of $239,623,996. This substantial deficit indicates a history of unprofitability and a long road to achieving sustainable earnings.

Industry Context

Soligenix operates in the biopharmaceutical industry, a sector characterized by high R&D costs, long development cycles, and significant regulatory oversight. The company is focused on developing novel therapeutics for rare diseases and inflammatory conditions. The competitive landscape is intense, with many companies vying for breakthroughs in oncology and immunology. Industry trends include a growing focus on targeted therapies and personalized medicine.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Soligenix is subject to stringent regulatory review by bodies like the FDA. The success of its drug candidates, particularly HyBryte, hinges on successful clinical trials and subsequent regulatory approval. Any delays or failures in the regulatory process pose a significant risk to the company's viability.

What Investors Should Do

1. Monitor clinical trial progress and results for HyBryte.
2. Assess cash burn rate and future financing needs.
3. Evaluate the competitive landscape and market potential for HyBryte.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reported net loss of $5,653,244 and cash balance of $5,097,670. R&D expenses significantly increased.
• 2025-08-07: ATM Facility Exhausted — Company raised an additional $1,439,300, exhausting its At Market Issuance Sales Agreement, highlighting ongoing need for capital.
• 2026-H2: Anticipated Top-Line Results for FLASH2 Study — Key milestone for HyBryte in CTCL; positive results could be a significant catalyst, while negative results would be detrimental.

Glossary

Accumulated Deficit

The total net losses of a company since its inception, minus any net profits. It represents the cumulative losses that have not been offset by profits. (Indicates the company's historical unprofitability, with a significant accumulated deficit of $239,623,996 as of June 30, 2025.)

At Market Issuance Sales Agreement (ATM)

A method for a company to sell its shares to the public gradually over time at prevailing market prices, typically through an underwriter. (SNGX utilized its ATM facility to raise $3,243,177 in the first half of 2025 and an additional $1,439,300 subsequently, indicating reliance on equity financing.)

CTCL

Cutaneous T-cell Lymphoma, a type of non-Hodgkin lymphoma that affects the skin. (HyBryte, SNGX's lead drug candidate, is being studied in Phase 3 trials for CTCL.)

Phase 3 Study

The third stage of clinical drug testing, involving a large number of patients to confirm efficacy, monitor side effects, compare it to other treatments, and collect information that will allow the drug to be used safely. (SNGX is conducting a Phase 3 FLASH2 study for HyBryte, a critical step towards potential regulatory approval.)

Year-Over-Year Comparison

For the six months ended June 30, 2025, Soligenix, Inc. saw a substantial increase in its net loss to $5,653,244, up 58.8% from $3,559,829 in the prior year period. This was primarily driven by a 126.7% surge in research and development expenses. Revenue from grants has completely disappeared, falling from $119,371 to $0. The company's cash position has declined from $7,819,514 at year-end 2024 to $5,097,670, while its accumulated deficit has grown to $239,623,996. New risks related to the ongoing clinical trials and the company's reliance on equity financing through its ATM facility are prominent.

Filing Documents

• sngx-20250630x10q.htm (10-Q) — 1710KB
• sngx-20250630xex10d1.htm (EX-10.1) — 64KB
• sngx-20250630xex31d1.htm (EX-31.1) — 18KB
• sngx-20250630xex31d2.htm (EX-31.2) — 19KB
• sngx-20250630xex32d1.htm (EX-32.1) — 8KB
• sngx-20250630xex32d2.htm (EX-32.2) — 11KB
• 0001558370-25-011554.txt ( ) — 7156KB
• sngx-20250630.xsd (EX-101.SCH) — 30KB
• sngx-20250630_cal.xml (EX-101.CAL) — 37KB
• sngx-20250630_def.xml (EX-101.DEF) — 147KB
• sngx-20250630_lab.xml (EX-101.LAB) — 314KB
• sngx-20250630_pre.xml (EX-101.PRE) — 238KB
• sngx-20250630x10q_htm.xml (XML) — 1537KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 45 Item 4

Controls and Procedures

Controls and Procedures 45 Part II OTHER INFORMATION Item 1

Legal Proceedings

Legal Proceedings 46 Item 1A

Risk Factors

Risk Factors 46 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 47 Item 5 Other Information 47 Item 6 Exhibits 48

SIGNATURES

SIGNATURES 49 i Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

- FINANCIAL STATEMENTS

ITEM 1 - FINANCIAL STATEMENTS Soligenix, Inc. and Subsidiaries Condensed Consolidated Balance Sheets June 30, December 31, 2025 2024 Assets (unaudited) Current assets: Cash and cash equivalents $ 5,097,670 $ 7,819,514 Deferred issuance cost 31,682 103,847 Prepaid expenses and other current assets 191,100 905,269 Total current assets 5,320,452 8,828,630 Security deposit 22,777 22,777 Office furniture and equipment, net 8,114 6,113 Right-of-use lease assets 409,304 108,963 Total assets $ 5,760,647 $ 8,966,483 Liabilities and shareholders' equity Current liabilities: Accounts payable $ 649,955 $ 667,896 Accrued expenses 2,783,149 2,359,339 Accrued compensation 87,189 336,442 Lease liabilities, current 108,814 111,862 Convertible debt — 1,372,873 Total current liabilities 3,629,107 4,848,412 Non-current liabilities: Lease liabilities, net of current portion 302,589 — Total liabilities 3,931,696 4,848,412 Commitments and contingencies (Note 6) Shareholders' equity: Preferred stock, 350,000 shares authorized; none issued or outstanding at June 30, 2025 and December 31, 2024, respectively — — Common stock, $ .001 par value; 75,000,000 shares authorized; 3,504,950 and 2,514,499 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 3,505 2,514 Additional paid-in capital 241,403,653 238,040,520 Accumulated other comprehensive income 45,789 45,789 Accumulated deficit ( 239,623,996 ) ( 233,970,752 ) Total shareholders' equity 1,828,951 4,118,071 Total liabilities and shareholders' equity $ 5,760,647 $ 8,966,483 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Table of Contents Soligenix, Inc. and Subsidiaries Condensed Consolidated Statements of Operations For the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) Three Months

View Full Filing

View this 10-Q filing on SEC EDGAR